Overview
Overview
Cerebrolysin is a porcine brain‑derived peptide preparation containing low‑molecular‑weight neuropeptides and free amino acids that crosses the blood–brain barrier to support neuronal survival[1]. It mimics endogenous neurotrophic factors (e.g., NGF, BDNF) and modulates neuroinflammatory mediators[1][2]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements. Reconstitute: Add 3.0 mL bacteriostatic water → 20 mg/mL
- Category
- Cognitive
- Routes
- subcutaneous
Mechanism
Cerebrolysin
Mechanism of action
Mechanism of action
Cerebrolysin is a multicomponent peptide preparation derived from porcine brain tissue, containing biologically active neuropeptides and amino acids with molecular weights below 10 kDa [1] . This low molecular weight allows it to cross the blood–brain barrier and exert neurotrophic effects similar to endogenous factors like nerve growth factor (NGF) and brain‑derived neurotrophic factor (BDNF) [1] [2] . Preclinical studies demonstrate neuroprotective effects including reduced infarct size and improved recovery in ischemia models [4] [5] . Human trials have examined its use in stroke, dementia, and traumatic brain injury with mixed but generally favorable tolerability profiles [2] [3] .
Key research findings
- 01
Cerebrolysin is not a single peptide but a standardized mixture of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of purified porcine (pig) brain proteins; it is studied for neurotrophic-like activity (in vitro / animal model).
- 02
Preclinical studies report neuroprotective and neurotrophic effects, including support of neuronal survival and plasticity markers in cell and rodent models (in vitro / animal model).
- 03
It has been evaluated in numerous randomized controlled trials in humans against research endpoints in acute ischemic stroke, traumatic brain injury, and vascular cognitive impairment/dementia (human study).
- 04
Cochrane systematic reviews have assessed Cerebrolysin in acute ischaemic stroke and in vascular dementia; these reviews generally flag methodological and risk-of-bias concerns and conclude that the evidence base is limited or inconclusive (human study / systematic review).
- 05
Across the trial literature, observed effects in research have generally been described as mild, though independent reviewers note substantial heterogeneity in study quality (human study).
Primary source: Cerebrolysin has one of the larger human research bases among compounds in this category, with multiple randomized controlled trials and Cochrane systematic reviews (e.g., in acute ischaemic stroke and vascular dementia). However, those reviews highlight inconsistent results and methodological limitations, so conclusions remain contested rather than settled.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Preclinical models consistently show neuroprotective effects including reduced neuronal damage and improved functional recovery after ischemic insult[4][5].
Meta‑analyses of human dementia trials suggest modest cognitive benefits with daily IV infusions[2]; stroke trial results have been more variable[3].
Protocol Reference
Protocol reference
Commonly cited research range: 20–32 mg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Week 1
20 mg (20,000 mcg)
Week 2
24 mg (24,000 mcg)
Week 3
28 mg (28,000 mcg)
Week 4+
32 mg (32,000 mcg)
| Phase | Reference amount | Units / volume |
|---|---|---|
| Week 1 | 20 mg (20,000 mcg) | 100 units (1.0 mL) × 1 |
| Week 2 | 24 mg (24,000 mcg) | 60 units (0.6 mL) AM + 60 units (0.6 mL) PM |
| Week 3 | 28 mg (28,000 mcg) | 70 units (0.7 mL) AM + 70 units (0.7 mL) PM |
| Week 4+ | 32 mg (32,000 mcg) | 80 units (0.8 mL) AM + 80 units (0.8 mL) PM |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake).
- 04💧Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 7 days[8].
- 05🔄Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at controlled room temperature ≤25 °C (≤77 °F) in dry, dark conditions; do not freeze [8] .
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days ; protect from light [8] .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Investigated in preclinical and clinical neurodegeneration and post-injury research, with mixed, context-dependent findings.
Cerebrolysin has one of the larger human research bases among compounds in this category, with multiple randomized controlled trials and Cochrane systematic reviews (e.g., in acute ischaemic stroke and vascular dementia). However, those reviews highlight inconsistent results and methodological limitations, so conclusions remain contested rather than settled.
- 01Cerebrolysin is not a single peptide but a standardized mixture of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of purified porcine (pig) brain proteins; it is studied for neurotrophic-like activity (in vitro / animal model).
- 02Preclinical studies report neuroprotective and neurotrophic effects, including support of neuronal survival and plasticity markers in cell and rodent models (in vitro / animal model).
- 03It has been evaluated in numerous randomized controlled trials in humans against research endpoints in acute ischemic stroke, traumatic brain injury, and vascular cognitive impairment/dementia (human study).
- 04Cochrane systematic reviews have assessed Cerebrolysin in acute ischaemic stroke and in vascular dementia; these reviews generally flag methodological and risk-of-bias concerns and conclude that the evidence base is limited or inconclusive (human study / systematic review).
- 05Across the trial literature, observed effects in research have generally been described as mild, though independent reviewers note substantial heterogeneity in study quality (human study).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to Cerebrolysin.
- 01International Peptide Society — Cerebrolysin Monograph: mechanism, pharmacology, and clinical applications (2018) View Sourceet al. (2018)
- 02Alzheimer’s Drug Discovery Foundation — Cerebrolysin cognitive vitality report: evidence synthesis and safety overview (2016) View Sourceet al. (2016)
- 03Zhang et al., Med Sci Monit (PMC) — Meta‑analysis of Cerebrolysin efficacy and safety in acute ischemic stroke (2017) View Sourceet al. (2017)
- 04Kurkin et al., PLOS One — Neuroprotective action of Cerebrolysin in acute/chronic brain ischemia in rats (2021) View Sourceet al. (2021)
- 05Espinoza et al., Behav Brain Res (PubMed) — Cerebrolysin neuroprotection and neurorepair in diabetic rat model (2024) View Sourceet al. (2024)
- 06CDC — Injection safety: preventing unsafe injection practices in clinical settings (2024) View Sourceet al. (2024)
- 07WHO — Injection safety: best practices for healthcare providers guide (2016) View Sourceet al. (2016)
- 08Ever Neuro Pharma — Cerebrolysin dosage recommendation and storage specifications (SPC 2016) View Sourceet al. (2016)
- 09NCBI Bookshelf — Subcutaneous injection technique: preparation, administration, and site rotation View Source
- 10Subcutaneous Drug Delivery Review (PMC) — Pharmacologic considerations and best practices for subcutaneous administration View Source
- 11Cognitive Frailty & Cerebrolysin Review (PMC) — Evidence for peptidergic nootropics in age‑related cognitive decline View Source
- 12Neurotrophic Factors & Neurodegeneration (PMC) — Role of NGF/BDNF pathways in neuroprotection and neuroplasticity View Source
- 13Pure Lab Peptides — Cerebrolysin (60 mg) product page (quality documentation and batch COAs) View Source
Observed Effects
Observed effects in cited research
Reported
- Generally well tolerated in short‑term use[2]; occasional mild injection‑site reactions (re
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Has been studied in clinical research; on this platform it is handled strictly as a research material. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| Cerebrolysinthis | A porcine brain-derived preparation of low-molecular-weight neuropeptides and free amino acids studied for neurotrophic activity supporting neuronal survival, synaptic plasticity, and modulation of neuroinflammation. | subcutaneous | Investigational / RUO |
| DSIP | A naturally occurring nonapeptide studied for influence on sleep architecture and hypothalamic-pituitary-adrenal (stress-axis) modulation; its precise receptor targets remain incompletely characterized. | subcutaneous | Investigational / RUO |
| PE-22-28 | A synthetic heptapeptide (GVSWGLR) derived from the sortilin propeptide that acts as a selective antagonist of TREK-1 potassium channels, a mechanism studied for mood regulation and neuroplasticity. | subcutaneous | Investigational / RUO |
| Pinealon | A synthetic tripeptide bioregulator (Glu-Asp-Arg) studied for cell-penetrating, gene-regulatory activity in neural tissue, with proposed antioxidant and neuroprotective effects. | subcutaneous | Investigational / RUO |
| Selank | Modulates GABA and serotonin systems. Increases BDNF. Provides anxiolytic effects without sedation or cognitive impairment. | nasal, subcutaneous | Investigational / RUO |
| Chonluten | A short tripeptide bioregulator (Glu-Asp-Gly) studied for effects on bronchopulmonary tissue and modulation of inflammatory signaling in monocyte/macrophage models. | subcutaneous | Investigational / RUO |
| CJC-1295 | Binds to GHRH receptors to stimulate GH release. Modified structure provides extended duration of action (up to 7 days). | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
Cerebrolysin is a standardized mixture of low-molecular-weight peptides and amino acids derived enzymatically from porcine brain tissue, studied for neurotrophic-like properties. It is a biological preparation rather than a single defined peptide.
Research describes neurotrophic-like and neuroprotective activity, including effects on neuronal survival, plasticity, and neurotrophic signaling in preclinical models. Mechanistic detail is still being characterized.
Cerebrolysin has been studied in numerous randomized controlled trials and in Cochrane systematic reviews for stroke and vascular dementia research endpoints. Those reviews generally find the evidence limited or inconclusive and flag quality concerns, so it should not be presented as established.
Yes. It is produced from purified porcine (pig) brain proteins, which is relevant for sourcing, handling, and any sensitivity considerations in a research context.
Trial protocols vary widely in dose and duration and are typically administered parenterally in clinical research settings. PeptiJournal does not provide dosing instructions; refer to the protocol reference. This is not medical advice.
Cerebrolysin is generally supplied as a sterile solution and stored per the manufacturer's labeling (cool, protected from light). Follow the product documentation and protocol reference.
Cerebrolysin is not FDA-approved in the United States. It is marketed as a medicine in a number of other countries; that approval does not extend to the US, where it is handled as a research material.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.